[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Sol-Gel Technologies Ltd (SLGL)

Sol-Gel Technologies Ltd (SLGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 194,164
  • Shares Outstanding, K 2,810
  • Annual Sales, $ 19,390 K
  • Annual Income, $ -6,130 K
  • EBIT $ -18 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.12
  • Price/Sales 9.97
  • Price/Cash Flow N/A
  • Price/Book 4.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-2.58
  • Number of Estimates 2
  • High Estimate $-1.71
  • Low Estimate $-3.45
  • Prior Year $-2.13
  • Growth Rate Est. (year over year) -21.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.15 +4.46%
on 08/28/26
90.79 -23.89%
on 08/14/26
-13.15 (-15.99%)
since 07/31/26
3-Month
66.00 +4.70%
on 06/01/26
93.74 -26.29%
on 07/22/26
-4.76 (-6.44%)
since 05/29/26
52-Week
21.10 +227.49%
on 08/29/25
97.97 -29.47%
on 03/03/26
+47.20 (+215.53%)
since 08/28/25

Most Recent Stories

More News
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout...

SLGL : 69.10 (+0.42%)
CPI on Tap for Canadians This Week

Monday U.S. Economic Lookahead Home builder confidence index (Aug.) Featured U.S Earnings ...

BABA : 112.56 (-1.28%)
DE : 664.91 (+1.53%)
TJX : 134.11 (+0.15%)
ADI : 352.51 (-2.36%)
BIDU : 95.34 (+0.06%)
FN : 403.87 (-2.19%)
BJ : 91.46 (+0.89%)
LOW : 203.26 (-0.70%)
KEYS : 319.00 (-1.15%)
XP : 18.46 (+1.26%)
SLGL : 69.10 (+0.42%)
HTHT : 47.70 (+0.80%)
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until...

SLGL : 69.10 (+0.42%)
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering

Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering...

SLGL : 69.10 (+0.42%)
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025...

SLGL : 69.10 (+0.42%)
This Under-the-Radar Stock Has Surged 1,300% Over the Past Year

Sol-Gel Technologies (SLGL) is a clinical-stage dermatology company focused on topical drugs for skin diseases. SLGL demonstrates exceptional technical momentum and is up 1,310% over the past 52 weeks....

SLGL : 69.10 (+0.42%)
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates...

SLGL : 69.10 (+0.42%)
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates...

SLGL : 69.10 (+0.42%)
Sol-Gel Reports First Quarter 2025 Results

Sol-Gel Reports First Quarter 2025 Results ...

SLGL : 69.10 (+0.42%)
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. ...

SLGL : 69.10 (+0.42%)
MYX : 9.94 (-0.40%)

Business Summary

Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for...

See More

Key Turning Points

3rd Resistance Point 75.28
2nd Resistance Point 73.11
1st Resistance Point 71.10
Last Price 69.10
1st Support Level 66.92
2nd Support Level 64.75
3rd Support Level 62.74

See More

52-Week High 97.97
Last Price 69.10
Fibonacci 61.8% 68.61
Fibonacci 50% 59.53
Fibonacci 38.2% 50.46
52-Week Low 21.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.